With inflation trends, interest rate signals and energy prices all pulling markets in different directions, many investors are looking for companies that combine solid financial footing with clear earnings growth potential. That is exactly what the Healthy high growth potential screener is designed to highlight. It focuses on stocks where analysts expect strong earnings growth over the next 3 years and balance sheets that pass basic quality checks. In this article, you will see 3 of the strongest candidates from this screener, along with plain English context to help decide whether any of these high growth stories deserve a place on your watchlist.

Alkane Resources (ASX:ALK)

Overview: Alkane Resources is an Australian gold exploration and production company that also looks for copper, nickel, zinc and silver, and invests in earlier stage gold projects, giving it a mix of current output and future optionality across several metals.

Market Cap: A$2.23b

Alkane Resources stands out because it combines a multi mine gold and antimony production base with a large Boda Kaiser gold copper project. Some analysts expect solid earnings and revenue growth over the next few years. The stock is priced below some fair value estimates and carries a lower P/E than many peers, which may appeal to value focused growth investors, yet there are real questions around past dilution, reliance on higher risk borrowing and a relatively young board. With fresh drilling success at Boda Kaiser and new antimony gold exploration at Nagambie, Alkane presents a complex story that investors may want to examine more closely.

Alkane’s mix of producing gold assets and the Boda Kaiser growth story can make the current valuation look like it is masking something important. Start with the 4 key rewards and 1 important major warning sign

Veeco Instruments (VECO)

Overview: Veeco Instruments supplies the specialized tools that chipmakers and electronics manufacturers use to build advanced semiconductors and thin film components, from laser annealing and ion beam systems to compound semiconductor and advanced packaging equipment. Its customers range from major integrated device manufacturers and foundries to outsourced chip assemblers, photonics producers, and research institutions across the globe.

Operations: Veeco generates essentially all of its US$655.3m in revenue from developing, manufacturing, selling, and supporting semiconductor and thin film process equipment, with customers spread across China, the rest of Asia Pacific, the United States, EMEA, and a small contribution from the rest of the world.

Market Cap: US$4.86b

Veeco Instruments appears on many growth watchlists because it sits in the tooling layer that enables trends like AI, high performance computing, and advanced photonics, while analysts still flag it as trading at a lower P/S than many direct peers. Forecasts for rapid revenue and earnings expansion are tied to growing orders for systems such as its NSA500 laser annealing platform and LUMINA+ MOCVD tools, supported by recent multi hundred million dollar bookings and reaffirmed guidance for 2026. The flip side is reliance on a concentrated set of large chip customers, thinner current profit margins at 3.5%, and a balance sheet funded entirely by higher risk external borrowing. For investors willing to accept these pressures, Veeco’s position in critical AI infrastructure equipment may warrant closer examination.

Veeco Instruments sits at the crossroads of AI infrastructure and chip manufacturing, yet its thinner 3.5% margins and reliance on external borrowing raise questions investors often overlook until they read the analyst forecasts for Veeco Instruments

Legend Biotech (LEGN)

Overview: Legend Biotech develops and commercializes cell therapies for cancer, led by its CAR-T treatment for multiple myeloma, while building a broader pipeline targeting blood cancers and solid tumors across the United States, China, and Europe.

Operations: Legend Biotech generates about US$1.14b in biotechnology revenue, with around US$856.9m from the United States, US$28.1m from China, and US$254m from other regions.

Market Cap: US$6.23b

Legend Biotech draws interest because its CAR-T therapy CARVYKTI is gaining global traction, revenue is forecast to grow and losses have been narrowing, and analysts see a path to profitability within 3 years with a potentially high 29.2% long run ROE if execution stays on track. The stock is also flagged as trading well below some fair value estimates. However, investors still need to weigh heavy dependence on a single commercial product, reliance on external funding including a recent US$226.0m follow on offering, and a relatively new management team. For anyone focused on high growth healthcare, the key consideration is whether Legend Biotech’s expanding cell therapy pipeline can offset those concentration and funding risks over time.

Legend Biotech’s accelerating CAR-T story and shrinking losses have many investors focused on the upside, but the real tension is what happens next. Be sure to check the analyst forecasts for Legend Biotech

The three stocks covered here are just a starting point, and the full Healthy high growth potential screen actually surfaced 1,512 more companies with similarly compelling growth and balance sheet stories waiting to be unpacked inside the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the exact catalysts and narratives that matter to you so you can focus on the highest conviction ideas without sifting through noise.

Take Control of Your Investment Journey

If Alkane Resources or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Catch On

Market leaders can shift fast, and the stocks catching quiet momentum today may be flying once the crowd finally reacts. Scan these fresh ideas while it matters and get in early.

• Target dependable cash flows and sturdy balance sheets by reviewing our curated list of solid balance sheet and fundamentals (19 results) that filters for businesses built to handle shocks without drama.
• Hunt for potential income workhorses with the hand picked 7 dividend fortresses designed for investors who want yield plus financial resilience, not just high headline payouts.
• Zero in on resilient operators using the focused 8 resilient stocks with low risk scores to spot companies where risk scores stay contained while the market’s attention is still elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.